A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
Public ClinicalTrials.gov record NCT04508023. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 Infection
Study identification
- NCT ID
- NCT04508023
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 1,284 participants
Conditions and interventions
Conditions
Interventions
- Rivaroxaban Drug
- Placebo Other
- Standard of Care (SOC) Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 12, 2020
- Primary completion
- May 31, 2022
- Completion
- May 31, 2022
- Last update posted
- Jul 17, 2023
2020 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona | Tucson | Arizona | 85721 | — |
| Southern California Permanente Medical Group | Los Angeles | California | 90027 | — |
| Kaiser Permanente Northern California | Oakland | California | 94612 | — |
| University of Colorado Denver | Aurora | Colorado | 80045 | — |
| Florida Hospital Orlando | Orlando | Florida | 32803 | — |
| Emory University | Atlanta | Georgia | 30308 | — |
| Morehouse School of Medicine | Atlanta | Georgia | 30310 | — |
| Atlanta VA Medical Center | Decatur | Georgia | 30033 | — |
| Northshore Universite Healthsystem | Evanston | Illinois | 60201 | — |
| Meritus Center for Clinical Research | Hagerstown | Maryland | 21742 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Lenox Hill Hospital -Northwell Health | New York | New York | 10075 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37235 | — |
| Texas Health Physicians Group | Fort Worth | Texas | 76107 | — |
| Franciscan Research Center | Tacoma | Washington | 98404 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04508023, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04508023 live on ClinicalTrials.gov.